Comparison of Clinical Risk Tools for Predicting Osteoporosis in Women Ages 50–64

References

1. 1.↵
   1. Cosman F,
   2. de Beur SJ,
   3. LeBoff MS,
   4. et al

   ; National Osteoporosis Foundation. Clinician's guide to prevention and treatment of osteoporosis. Osteoporos Int 2014;25:2359–81.

   OpenUrlCrossRefPubMed
2. 2.↵
   Committee on Practice Bulletins-Gynecology, The American College of Obstetricians and Gynecologists. ACOG Practice Bulletin N. 129. Osteoporosis. Obstet Gynecol 2012;120:718–34.

   OpenUrlPubMed
3. 3.↵
   U.S. Preventive Services Task Force. Screening for osteoporosis: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2011;154:356–64.

   OpenUrlCrossRefPubMedWeb of Science
4. 4.↵
   1. Lim LS,
   2. Hoeksema LJ,
   3. Sherin K

   . Screening for osteoporosis in the adult U.S. population: ACPM position statement on preventive practice. Am J Prev Med 2009;36:366–75.

   OpenUrlCrossRefPubMedWeb of Science
5. 5.↵
   1. Watts NB,
   2. Bilezikian JP,
   3. Camacho PM,
   4. et al

   . American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of postmenopausal osteoporosis: executive summary of recommendations. Endocr Pract 2010;16:1016–9.

   OpenUrlPubMed
6. 6.↵
   Clinician's guide to prevention and treatment of osteoporosis. Washington, DC: National Osteoporosis Foundation; 2014. Available from: http://nof.org/files/nof/public/content/file/2791/upload/919.pdf. Accessed October 12, 2015.
7. 7.↵
   FRAX. WHO Fracture Risk Assessment Tool. Sheffield, UK: World Health Organization Collaborating Centre for Metabolic Bone Diseases. Available from: https://www.shef.ac.uk/FRAX/tool.aspx. Accessed October 12, 2015.
8. 8.↵
   1. Crandall CJ,
   2. Larson J,
   3. Gourlay ML,
   4. et al

   . Osteoporosis Screening in postmenopausal women 50 to 64 years old: comparison of US Preventive Services Task Force strategy and two traditional strategies in the Women's Health Initiative. J Bone Miner Res 2014;29:1661–6.

   OpenUrlPubMed
9. 9.↵
   1. Bansal S,
   2. Pecina JL,
   3. Merry SP,
   4. et al

   . US Preventative Services Task Force FRAX threshold has a low sensitivity to detect osteoporosis in women ages 50–64 years. Osteoporos Int 2015;26:1429–33.

   OpenUrlPubMed
10. 10.↵
    1. Cadarette SM,
    2. Jaglal SB,
    3. Kreiger N,
    4. McIsaac WJ,
    5. Darlington GA,
    6. Tu JV

    . Development and validation of the Osteoporosis Risk Assessment Instrument to facilitate selection of women for bone densitometry. CMAJ 2000;162:1289–94.

    OpenUrlAbstract/FREE Full Text
11. 11.↵
    1. Koh LK,
    2. Sedrine WB,
    3. Torralba TP,
    4. et al

    . A simple tool to identify Asian women at increased risk of osteoporosis. Osteoporos Int 2001;12:699–705.

    OpenUrlCrossRefPubMedWeb of Science
12. 12.↵
    1. Lydick E,
    2. Cook K,
    3. Turpin J,
    4. Melton M,
    5. Stine R,
    6. Byrnes C

    . Development and validation of a simple questionnaire to facilitate identification of women likely to have low bone density. Am J Manag Care 1998;4:37–48.

    OpenUrlPubMedWeb of Science
13. 13.↵
    1. Kanis JA,
    2. Oden A,
    3. Johnell O,
    4. et al

    . The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. Osteoporos Int 2007;18:1033–46.

    OpenUrlCrossRefPubMedWeb of Science
14. 14.↵
    1. Kanis JA,
    2. McCloskey EV,
    3. Johansson H,
    4. Oden A,
    5. Strom O,
    6. Borgstrom F

    . Development and use of FRAX in osteoporosis. Osteoporos Int 2010;21(Suppl 2):S407–13.

    OpenUrlCrossRefPubMed
15. 15.↵
    1. Gourlay ML,
    2. Miller WC,
    3. Richy F,
    4. Garrett JM,
    5. Hanson LC,
    6. Reginster JY

    . Performance of osteoporosis risk assessment tools in postmenopausal women aged 45–64 years. Osteoporos Int 2005;16:921–7.

    OpenUrlCrossRefPubMed
16. 16.↵
    1. Geusens P,
    2. Hochberg MC,
    3. van der Voort DJ,
    4. et al

    . Performance of risk indices for identifying low bone density in postmenopausal women. Mayo Clinic Proc 2002;77:629–37.

    OpenUrlCrossRefPubMedWeb of Science
17. 17.↵
    Medscape. Osteoporosis risk SCORE (Simple Calculated Osteoporosis Risk Calculation). Available from: http://reference.medscape.com/calculator/osteoporosis-risk-score. Accessed June 24, 2015.
18. 18.↵
    1. Kanis JA,
    2. McCloskey EV,
    3. Johansson H,
    4. Strom O,
    5. Borgstrom F,
    6. Oden A

    . Case finding for the management of osteoporosis with FRAX–assessment and intervention thresholds for the UK. Osteoporos Int 2008;19:1395–408.

    OpenUrlCrossRefPubMedWeb of Science
19. 19.↵
    1. Kanis JA,
    2. Harvey NC,
    3. McCloskey E

    . Pre-screening young postmenopausal women for BMD testing. Bonekey Rep 2014;3:544.

    OpenUrlPubMed
20. 20.↵
    1. Kanis JA

    , on behalf of the World Health Organization Scientific Group. Assessment of osteoporosis at the primary health care level. Technical report. Sheffield, UK: World Health Organization Collaborating Centre for Metabolic Bone Diseases, University of Sheffield; 2007.
21. 21.↵
    1. Epstein S

    . Is treatment of early postmenopausal women with bisphosphonates justified? Int J Clin Pract 2007;61:963–71.

    OpenUrlCrossRefPubMedWeb of Science
22. 22.↵
    1. Harris ST,
    2. Gertz BJ,
    3. Genant HK,
    4. et al

    . The effect of short term treatment with alendronate on vertebral density and biochemical markers of bone remodeling in early postmenopausal women. J Clin Endocrinol Metab 1993;76:1399–406.

    OpenUrlCrossRefPubMedWeb of Science
23. 23.↵
    1. Wasnich RD,
    2. Miller PD

    . Antifracture efficacy of antiresorptive agents are related to changes in bone density. J Clin Endocrinol Metab 2000;85:231–6.

    OpenUrlCrossRefPubMedWeb of Science
24. 24.↵
    1. Hochberg MC,
    2. Greenspan S,
    3. Wasnich RD,
    4. Miller P,
    5. Thompson DE,
    6. Ross PD

    . Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents. J Clin Endocrinol Metab 2002;87:1586–92.

    OpenUrlCrossRefPubMedWeb of Science
25. 25.↵
    1. Hochberg MC,
    2. Thompson DE,
    3. Black DM,
    4. et al

    . Effect of alendronate on the age-specific incidence of symptomatic osteoporotic fractures. J Bone Miner Res 2005;20:971–6.

    OpenUrlCrossRefPubMedWeb of Science
26. 26.↵
    1. Cummings SR,
    2. Black DM,
    3. Thompson DE,
    4. et al

    . Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 1998;280:2077–82.

    OpenUrlCrossRefPubMedWeb of Science